INCREASED PROLIFERATION OF A HUMAN BREAST-CARCINOMA CELL-LINE BY RECOMBINANT INTERLEUKIN-2

被引:18
|
作者
KATANO, M
MATSUO, T
MORISAKI, T
NAITO, K
NAGUMO, F
KUBOTA, E
NAKAMURA, M
HISATSUGU, T
TADANO, J
机构
[1] KYUSHU UNIV,SCH MED,DEPT SURG 1,FUKUOKA 812,JAPAN
[2] SAGA MED SCH,DEPT INTERNAL MED,SAGA 849,JAPAN
[3] SAGA MED SCH,HOSP LAB,SAGA 849,JAPAN
[4] SAGA MED SCH,DEPT ORAL & MAXILLOFACIAL SURG,SAGA 849,JAPAN
关键词
BREAST CARCINOMA CELL LINE; INTERLEUKIN-2; RECEPTOR; AUTOCRINE GROWTH FACTOR; SECRETION;
D O I
10.1007/BF01533381
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Two adenocarcinoma cell lines, Breast M25-SF and Breast M, were established from tumor tissue resected surgically from a patient with breast cancer. One, Breast M25-SF, expresses interleukin-2 receptor (IL-2R) on the cell surface and the other, Breast M, does not. The effects of recombinant interleukin-2 (rIL-2) on the proliferation of these cell lines were investigated. The growth of Breast M25-SF was significantly promoted by rIL-2 ranging from 1.25 U/ml to 640 U/ml. Anti-CD25 (Tac) antibody significantly blocked the growth enhancement of Breast M25-SF by rIL-2. Breast M, however, did not respond to rIL-2. To confirm more directly the promotion of Breast M25-SF growth by rIL-2, cloning of IL-2 responders from parent Breast M25-SF cells was carried out by limiting dilution without feeder cells in 96-well microplates. No colony formation was found in 24 wells without rIL-2. Eleven, 13 and 6 clones were established from groups of 24 wells containing rIL-2 at 200, 20 and 2 U/ml respectively. All of the clones expressed IL-2R and respond to rIL-2. By using a sensitive polymerase chain reaction technique, we demonstrated that Breast M25-SF but not Breast M expressed IL-2 mRNA, and IL-2 secretion from Breast M25-SF but not Breast M was also confirmed by radioimmunoassay. These findings suggest a role for IL-2 in autocrine support of Breast M25-SF growth. IL-2 may play an important role in the growth control of breast carcinoma cells.
引用
收藏
页码:161 / 166
页数:6
相关论文
共 50 条
  • [41] Effects of stimulating interleukin-2/anti-interleukin-2 antibody complexes on renal cell carcinoma
    Han, Kyu-Hyun
    Kim, Ki Won
    Yan, Ji-Jing
    Lee, Jae-Ghi
    Lee, Eun Mi
    Han, Miyeon
    Cho, Eun Jin
    Kang, Seong Sik
    Lim, Hye Jin
    Koo, Tai Yeon
    Ahn, Curie
    Yang, Jaeseok
    BMC UROLOGY, 2016, 16
  • [42] Secretion of human interleukin-2 fused with green fluorescent protein in recombinant Pichia pastoris
    Cha, HJ
    Dalal, NN
    Bentley, WE
    APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2005, 126 (01) : 1 - 11
  • [43] PURIFICATION AND CHARACTERIZATION OF A HIGH-MOLECULAR-WEIGHT FORM OF RECOMBINANT HUMAN INTERLEUKIN-2
    AHMAD, Z
    CIOLEK, D
    PAN, YCE
    MICHEL, H
    KHAN, FR
    JOURNAL OF PROTEIN CHEMISTRY, 1994, 13 (07): : 591 - 598
  • [44] Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma
    Eton, O
    Rosenblum, MG
    Legha, SS
    Zhang, WH
    East, MJ
    Bedikian, A
    Papadopoulos, N
    Buzaid, A
    Benjamin, RS
    CANCER, 2002, 95 (01) : 127 - 134
  • [45] CYTOKINE AND NATURAL KILLING REGULATION OF GROWTH OF A HAIRY-CELL LEUKEMIA-LIKE CELL-LINE - THE ROLE OF INTERFERON-ALPHA AND INTERLEUKIN-2
    REITER, Z
    OZES, ON
    BLATT, LM
    TAYLOR, MW
    JOURNAL OF IMMUNOTHERAPY, 1992, 11 (01) : 40 - 49
  • [46] Role of interleukin-18 in human natural killer cell is associated with interleukin-2
    Huang, Yong
    Lei, YingFeng
    Zhang, Hai
    Zhang, Mingjie
    Dayton, Andrew
    MOLECULAR IMMUNOLOGY, 2010, 47 (16) : 2604 - 2610
  • [47] Subcutaneous interleukin-2 and interferon in the treatment of patients with metastatic renal cell carcinoma -: Less efficacy compared with intravenous interleukin-2 and interferon α
    Ravaud, A
    Delva, R
    Gomez, F
    Chevreau, C
    Douillard, JY
    Peny, J
    Coudert, B
    Négrier, S
    CANCER, 2002, 95 (11) : 2324 - 2330
  • [48] Interleukin-2, interferon-α and interleukin-2 plus interferon-α in renal cell carcinoma.: A randomized phase II trial
    Boccardo, F
    Rubagotti, A
    Canobbio, L
    Galligioni, E
    Sorio, R
    Lucenti, A
    Cognetti, F
    Ruggeri, E
    Landonio, G
    Baiocchi, C
    Besana, C
    Citterio, G
    De Rosa, M
    Calabresi, F
    TUMORI, 1998, 84 (05) : 534 - 539
  • [49] PHASE-II STUDY OF RECOMBINANT ALPHA-INTERFERON AND RECOMBINANT INTERLEUKIN-2 IN METASTATIC BREAST-CANCER
    WALTERS, RS
    THERIAULT, RL
    HOLMES, FA
    ESPARZA, L
    HORTOBAGYI, GN
    JOURNAL OF IMMUNOTHERAPY, 1994, 16 (04): : 303 - 305
  • [50] Culturing the Human Natural Killer Cell Line NK-92 in Interleukin-2 and Interleukin-15-Implications for Clinical Trials
    Tornroos, Heidi
    Hagerstrand, Henry
    Lindqvist, Christer
    ANTICANCER RESEARCH, 2019, 39 (01) : 107 - 112